Moreover, Palafox et al. showed that p16 overexpression was associated with reduced response to CDK4/6 inhibitors in patient-derived xenografts and breast cancer cell lines, while heterozygous Rb1 loss served as a biomarker for acquired resistance and poor clinical outcomes [26]. Here, CDK4 is linked to breast carcinoma.